Blood Test Using Plasma exoRNA to Detect Significant Prostate Cancer in Men

What this Trial Is About

Researchers are investigating a plasma exosome RNA signature to diagnose clinically significant prostate cancer. This observational study aims to evaluate the diagnostic accuracy of a plasma exo-RNA panel alone in identifying this condition. Additionally, the study compares this RNA panels performance with other imaging methods or blood tests to assess its effectiveness at the time of prostate biopsy. Participants suspected of having prostate cancer based on clinical symptoms, digital rectal exam, ultrasound, or MRI will be observed. The study involves collecting blood samples to analyze the plasma exo-RNA panel. There is one study cohort receiving diagnosis from the serum RNA combination without additional intervention. The study does not include drug or treatment administration. During the study, participants will undergo prostate biopsy and clinical assessments to confirm diagnosis. Researchers will measure the diagnostic efficacy of the plasma exo-RNA panel and compare it with other diagnostic tools. The study involves monitoring at the time of prostate biopsy, with no further treatment or intervention specified. Participation duration varies depending on individual diagnostic procedures and follow-up needs.

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer